Today, the National Alliance of State & Territorial AIDS Directors (NASTAD) released the 2014 ADAP Formulary Database and an accompanying user’s guide online. The Database was created as part of NASTAD’s National ADAP Monitoring Project, a longstanding effort to document new developments and challenges facing ADAPs, assessing key trends over time, and providing the latest available data on the status of ADAPs. The Database details ADAPs’ coverage of medications both individually and by drug class including antiretroviral (ARV) treatment, “A1” Opportunistic Infections (A1 OI) medications, treatments for hepatitis B and C, mental health and substance use treatment medications as well as vaccines and various laboratory tests.
For step-by-step directions and guidance on how to access and use the ADAP Formulary Database, please click here.
A press release regarding the availability of the ADAP Formulary Database will be distributed to the media, partners and the HIV community this afternoon. Click here to view the online version of this press release. Please note that all of the resources related to the National ADAP Monitoring Project can be found on the NASTAD website.
Please contact Britten Pund if you have any questions.
For immediate release: June 10, 2014
Contact: Britten Pund, 202-434-8044, bpund@NASTAD.org
NASTAD Releases 2014 Online AIDS Drug Assistance Program (ADAP) Formulary Database
Washington, DC – Today, the National Alliance of State & Territorial AIDS Directors (NASTAD) released the 2014 Online AIDS Drug Assistance Program (ADAP) Formulary Database (the Database) and accompanying User’s Guide. The Database details ADAP coverage of medications both individually and by drug class, marking the first time state-by-state ADAP formulary coverage data has been made publicly available in an online searchable format. NASTAD receives frequent requests regarding individual states’ formulary composition. This newly-released online format provides a method to query this data. Medications included in the Database include antiretroviral (ARV) treatments and “A1” Opportunistic Infections (A1 OI) medications, as well as treatments for hepatitis B and C, substance use treatment medications and various vaccines and laboratory tests. The Database includes formulary information from all 50 states as well as the District of Columbia, Guam and Puerto Rico, as of March 31, 2014. Moving forward, the Database will be updated as new information becomes available. In addition, interested parties are encouraged to contact individual ADAPs with specific questions about medication availability.
Key findings from the ADAP Formulary Database include:
- 2 ADAPs have “open formularies” in which all FDA-approved medications are included, excluding designated exceptions
- 52 ADAPs cover one or more medication in each ARV drug class 
- 50 ADAPs cover more than one drug in each of the following drug classes: HIV Integrase Strand Inhibitor; Protease Inhibitor; Nucleoside Reverse Transcriptase Inhibitor (NRTI); and non-nucleoside reverse transcriptase inhibitor (NNRTI)
- 38 ADAPs cover one or more hepatitis B treatment while 30 ADAPs cover one or more hepatitis C treatment
- 11 ADAPs cover one or more substance use treatment medication while 25 cover one or more mental health treatment medication
- 28 ADAPs cover one or more vaccine, e.g., for hepatitis A and/or B
- 21 ADAPs cover one or more HIV diagnostic test while 11 cover one or more hepatitis C diagnostic test
- 46 ADAPs cover one or more medication from other drug classes such as antibiotics, cardiac medications and topical steroids.
The Database was developed using the Google application “Fusion Tables” and was created as part of NASTAD’s National ADAP Monitoring Project, a long-standing effort to document new developments and challenges facing ADAPs, assessing key trends over time and providing the latest available data on ADAPs.
ADAPs continue to play a critical role in efforts to end the domestic HIV/AIDS epidemic by providing and maintaining access to medications PLWH. Effective antiretroviral therapy is associated with optimal health outcomes such as viral load suppression, which in turn greatly reduces HIV transmission and rates for new infections. Yet PLWH experience other health concerns beyond HIV, many of which also require access to medications and treatment. As ARVs have greatly extended the life expectancy of PLWH, other conditions that occur as a result of aging are increasingly important to address and treat. Finally, issues related to viral hepatitis, substance use and mental health pose challenges to PLWH in terms of their broader health and well-being and the overall effectiveness of ARV treatment.
“While the Affordable Care Act (ACA) provides opportunities for expansions in both public and private health care coverage for people living with HIV, ADAPs continue to serve this population to ensure there are no gaps in coverage or access to treatment,” noted Julie Scofield, NASTAD’s Executive Director. “There will continue to be ADAP clients where Medicaid and private insurance are not a viable option, making it necessary for ADAPs to continue to provide a broad array of medications to meet the complete health needs of this population.”
Learn more about the National ADAP Monitoring Project here.